Im Cannabis Corp
$ 0.80
-3.61%
24 Feb - close price
- Market Cap 4,892,700 USD
- Current Price $ 0.80
- High / Low $ 0.87 / 0.77
- Stock P/E N/A
- Book Value 0.55
- EPS -0.50
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -1.20 %
- 52 Week High 7.12
- 52 Week Low 0.80
About
IM Cannabis Corp. The company is headquartered in Tel Aviv-Yafo, Israel.
Analyst Target Price
$8.22
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-12 | 2025-05-06 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-05-08 | 2024-03-28 | 2023-11-13 | 2023-08-14 | 2023-05-15 | 2023-03-29 |
| Reported EPS | -0.75 | -0.09 | -0.2343 | -0.22 | -0.41 | -0.23 | -0.42 | -0.18 | -0.16 | -0.26 | 0.03 | -1.32 |
| Estimated EPS | None | None | None | -0.54 | -0.96 | -1.17 | -0.2 | -0.12 | -0.21 | -0.07 | -0.26 | -0.28 |
| Surprise | 0 | 0 | 0 | 0.32 | 0.55 | 0.94 | -0.22 | -0.06 | 0.05 | -0.19 | 0.29 | -1.04 |
| Surprise Percentage | None% | None% | None% | 59.2593% | 57.2917% | 80.3419% | -110% | -50% | 23.8095% | -271.4286% | 111.5385% | -371.4286% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IMCC
2026-02-23 04:28:22
IM Cannabis Corp, an Israeli multinational medical marijuana company, has applied to list its shares on the Nasdaq stock exchange. The company aims to join other cannabis firms on major U.S. exchanges, leveraging its positive EBITDA from operations in Germany and Israel. This move remains subject to regulatory approval, with trading expected under the symbol IMCC.
2026-02-16 14:37:18
IM Cannabis Corp. has regained compliance with Nasdaq Listing Rule 5550(b)(1), ensuring its common stock will continue to be traded on the Nasdaq Capital Market. The company, a leading medical cannabis provider in Israel and Germany, focuses on premium products and a data-driven approach to market presence and regulatory compliance. This compliance strengthens its financial standing and supports its ongoing operations and strategic initiatives.
2026-02-16 02:58:41
IM Cannabis Corp. has signed a non-binding term sheet to acquire a 60% equity stake in a quantum computing bio data company for up to $54 million. This strategic diversification aims to leverage quantum computing for enhancing biological data storage, analysis, and processing. The acquisition will involve cash, shares, and performance-based earn-outs, while IM Cannabis shares currently reflect a decrease of 10.16% on the Nasdaq.
2026-02-15 23:16:51
IM Cannabis Corp. announced it will release its third-quarter 2025 financial and operational results on Thursday, November 13th, prior to market open. The company, a leading medical cannabis provider in Israel and Germany, focuses on providing premium cannabis products through a comprehensive ecosystem. IM Cannabis aims for sustainable and profitable growth by utilizing a data-driven approach and a global supply chain while adhering to strict regulatory standards.
2026-02-15 21:27:28
IM Cannabis Corp. announced significant changes to its Board of Directors, with Shmulik Arbel and Brian Schinderle resigning and Asaf Yitzhaik and Eli Zamir appointed as their replacements, including new roles on key committees. Concurrently, the company is undertaking a strategic review to explore additional business activities aimed at boosting long-term growth and shareholder value. IM Cannabis will continue to focus on its existing medical cannabis operations in Israel and Germany during this period of strategic exploration.
2026-02-05 23:29:05
IM Cannabis (IMCC) has announced plans to sell 9.79 million common shares as part of its financial planning, allowing current shareholders to divest holdings. The company, operating in the medical cannabis sector primarily in Israel and Germany, faces significant financial challenges including negative revenue growth, profitability issues, high leverage, and a low Altman Z-Score suggesting bankruptcy risk. Despite a potentially undervalued P/S ratio, investors are advised to carefully consider the company's poor financial strength and high stock volatility.
